Sandoz Afatinib 30 mg (Afatinib (Afatinib Dimaleate) TABLET) 30 MG

Sandoz Afatinib 30 mg tablets are a pharmaceutical product used for targeted therapy. This medication is designed to help manage specific types of cancer by inhibiting certain cell growth signals.

Strength

30 MG

Manufacturer / TM Owner

SANDOZ CANADA INCORPORATED

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Afatinib (afatinib dimaleate) is primarily used in the treatment of non-small cell lung cancer and other types of cancer. It works by targeting specific proteins that help cancer cells grow and divide. Patients often wonder, 'What is afatinib used for?' This medication is typically prescribed for advanced or metastatic cancers where other treatments may not be effective.

Side Effects

Common effects of afatinib may include skin rash, diarrhea, and nausea. Some users may also experience dry skin, loss of appetite, or fatigue. These effects can vary in severity and duration, depending on individual responses to the medication.

Precautions & Warnings

Afatinib should be handled with care and stored as directed. It is important to follow the advice of a healthcare professional regarding administration and any potential side effects. Pregnant women or those planning to become pregnant should discuss the use of afatinib with their doctor.

Avoid Interactions

Afatinib may interact with certain medications, including those that are metabolized by the liver. It is advisable to inform healthcare providers about all current medications, including over-the-counter drugs and supplements. Alcohol and other substances that affect liver function should be used with caution.

Frequently Asked Questions

Afatinib is used to treat certain types of cancer, including non-small cell lung cancer, by targeting proteins that help cancer cells grow.

Afatinib is typically taken orally, usually once daily, as directed by a healthcare professional.

Common side effects may include skin rash, diarrhea, nausea, dry skin, loss of appetite, and fatigue.

Afatinib may interact with other medications, so it is important to consult a healthcare provider before combining it with other drugs.

Pregnant women or those planning to become pregnant should discuss the use of afatinib with their doctor due to potential risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.